Stimulant Use

Stimulant eligibility required moderate or severe stimulant use disorder screening or at least weekly methamphetamine or cocaine use in the past three months. There is no approved pharmacotherapy for stimulant use disorders. Stimulant use severity was included as a secondary outcome even though the intervention and remote contingency management were not focused on reducing stimulant use. Stimulant use, especially methamphetamine use, remains an important driver of HIV incidence among sexual minority men in the United States. The resurgent methamphetamine epidemic may disproportionately affect Black and Latino sexual minority men. Behavioral interventions are frontline treatments for stimulant use disorders.